Valo: adding tumor antigens to oncolytic viruses

With platforms that can rapidly display tumor-specific antigens on oncolytic viruses without genetic engineering, Valo is positioning itself as an attractive collaborator for immuno-oncology companies.

Oncolytic viruses kill cancer cells by lysing the cells, and are engineered to amplify antitumor immune responses through expression of immuno-stimulatory genes. ...